Global Cancer Biomarkers Market

  • ID: 4434695
  • Report
  • Region: Global
  • 165 pages
  • Mordor Intelligence
1 of 5


  • 23Andme
  • Agendia
  • Ambry Genetics
  • Decode Genetics
  • Genomic Health
  • Illumina Inc.
  • MORE
Global Cancer Biomarkers Market

Biomarkers are chemical, physical or biological parameters which can be used to indicate disease states. Oncology biomarkers offers high speed, non-invasive cancer diagnosis and believe to enhance cancer detection and screening. Major driving factors for the market are streamlined drug delivery process, noninvasive technology, increased rates of survival.


A cancer biomarker is an indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. These biomarkers are thus increasing the chances of survival rates of patients and thus driving this market. Enhanced accuracy and Speed of diagnosis and Boost in government and Private funds for biomarkers discovery are also some of the drivers of this market.


Cancer treatment contributes more to health care costs in the world and thus is one of the key restraining global cancer biomarkers market. Many patients who are suffering from cancer cannot afford treatment. Reimbursement issues and Need for immediate processing are also restraining this market.

Market Segmentation

Global biomarkers market is segmented based on type of applications, by services and based on Geography. Global Cancer Biomarker market is segmented based on Cancer biomarker discovery market, and cancer biomarker diagnostic market. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa and South America. The segment on North American region includes Canada, the United States and Mexico. The European region includes the United Kingdom, Germany, France, Italy, Spain, and rest of Europe. The Asia-Pacific region includes Australia, New Zealand, China, India, Japan, South Korea, and rest of Asia-Pacific. The Middle East and Africa (MEA) region includes GCC, South Africa and rest of MEA. South America region includes Brazil, Argentina and rest of South America.

Some of the key players in this market include:

Some of the major players in this market are Abbott Laboratories,Correlogic Systems, Inc, Agendia Bv,Biocurex Inc,Astellas Pharma Us Inc, Beckman Coulter, Inc, Becton, Dickinson And Company, Biomerieux S.A., Biomoda, Inc, Clarient, Inc, Ambrilia Biopharma,Diadexus, Inc, Affymetrix, Inc and Aureon Laboratories, Inc.

Key Deliverables

Market analysis for the market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers, restraints opportunities and challenges.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.

Identification and analysis of the macro and micro factors that affect the Cancer Biomarkers Market. Insights of the market in the regions that have the highest potential for growth and also identify the markets that are still untapped.
Note: Product cover images may vary from those shown
2 of 5


  • 23Andme
  • Agendia
  • Ambry Genetics
  • Decode Genetics
  • Genomic Health
  • Illumina Inc.
  • MORE
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 General Study Assumptions

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Market Overview
5.3 Porter’s Five Force Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Degree of Competition
5.3.4 Threat of Substitution
5.3.5 Threat of New Entrants

6. Drivers, Restraints, Opportunities, and Challenges (Droc) Analysis
6.1 Market Drivers
6.1.1 Increased Incidences Globally and Higher Acceptance for Treatment in Developing Regions
6.1.2 Paradigm Shift in Healthcare from Disease Diagnosis to Risk Assessment or Early Diagnosis
6.1.3 Increasing Usage in Drug Development
6.2 Market Restraints
6.2.1 High Cost of Diagnosis
6.2.2 Reimbursement Issues
6.2.3 Need for Immediate Processing
6.3 Opportunities
6.3.1 Genetics-Based In-Vitro Diagnostics
6.3.2 Research and Development
6.4 Challenges
6.4.1 Development of Novel Biomarkers
6.4.2 Regulatory and Reimbursement Issues
6.4.3 Translational Genetics

7. Market Segmentation
7.1 by Diseases
7.1.1 Prostate Cancer
7.1.2 Breast Cancer
7.1.3 Lung Cancer
7.1.4 Colorectal Cancer
7.1.5 Cervical Cancer
7.1.6 Others
7.2 by Applications
7.2.1 Risk Assessment
7.2.2 Prognostics
7.2.3 Disease Diagnosis
7.2.4 Drug Discovery and Development
7.3 by Services
7.3.1 Sample Preparation
7.3.2 Assay Development
7.3.3 Biomarkers Validation and Testing
7.4 by Type
7.4.1 Protein Biomarkers
7.4.2 Genetic Biomarkers
7.4.3 Others
7.5 by Profiling Technologies
7.5.1 Omics Technologies Genomics Proteomics Metabolomics Others
7.5.2 Imaging Technologies
7.5.3 Immunoassays
7.5.4 Cytogenetics
7.5.5 Bioinformatics
7.6 by Geography
7.6.1 North America U.S. Canada Mexico
7.6.2 Europe Germany Uk France Italy Spain Rest of Europe
7.6.3 Asia Pacific Japan China India South Korea Australia Rest of Asia Pacific
7.6.4 the Middle East & Africa Gcc South Africa Rest of Middle East & Africa
7.6.5 South America Brazil Argentina Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisitions
8.2 Agreements, Collaborations & Partnerships
8.3 New Product Launches
8.4 Recommendations to New Market Players

9. Company Profiles
9.1 Abbott Laboratories
9.2 Affymetrix Inc. (Acquired by Thermo Fisher Scientific)
9.3 Agilent Technologies
9.4 Hologic Inc.
9.5 Roche Holding
9.6 23Andme
9.7 Ambry Genetics
9.8 Biomerieux
9.9 Celera Corporation (Quest Diagnostics)
9.10 Decode Genetics
9.11 Foundation Medicine Inc.
9.12 Illumina Inc.
9.13 Genomic Health
9.14 Agendia

10. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Abbott Laboratories
  • Affymetrix Inc. (Acquired by Thermo Fisher Scientific)
  • Agilent Technologies
  • Hologic Inc.
  • Roche Holding
  • 23Andme
  • Ambry Genetics
  • Biomerieux
  • Celera Corporation (Quest Diagnostics)
  • Decode Genetics
  • Foundation Medicine Inc.
  • Illumina Inc.
  • Genomic Health
  • Agendia
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown